neurocrine biosciences

Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval

Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock a buy.

YAHOO!Finance · 5h

Neurocrine Biosciences (NBIX) Q4 Earnings and Revenues Lag Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -35.90% and 0.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

SFGate · 6h

Neurocrine: Q4 Earnings Snapshot

SAN DIEGO (AP) — SAN DIEGO (AP) — Neurocrine Biosciences Inc. (NBIX) on Thursday reported fourth-quarter earnings of $103.1 million. The San Diego-based company said it had profit of $1 per share.

Benzinga.com · 6h

Earnings Summary: Neurocrine Biosciences Q4

Neurocrine Biosciences missed estimated earnings by -1.0%, reporting an EPS of $1.69 versus an estimate of $1.71. Revenue was up $112.50 million from the same period last year. During the previous quarter, the company beat on EPS by $0.3, leading to a 3.0% drop share price change the next day.

Business Insider · 5h

Neurocrine Biosciences Inc Q4 Profit Decreases, Misses Estimates

Neurocrine Biosciences Inc (NBIX) reported earnings for fourth quarter that decreased from the same period last year and missed the

Neurocrine reports Q4 adjusted EPS $1.69, consensus $1.93

Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...

American Association of Individual Investors7h

Which Is a Better Investment, Biogen Inc. or Neurocrine Biosciences, Inc. Stock?

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Hosted on MSN5h

Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug

Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.

Neurocrine sees FY25 Ingrezza net product sales $2.5B-$2.6B

FY25 revenue consensus $2.79B.Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool ...

2don MSN

Neurocrine Biosciences officer sells $168,849 in stock

David W. Boyer, the Chief Corporate Affairs Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Tokio Marine Asset Management Co. Ltd.

Tokio Marine Asset Management Co. Ltd. cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.8% ...

FierceBiotech9d

Takeda regains home rights to phase 3-stage depression drug from Neurocrine

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...

Neurocrine price target raised to $184 from $182 at BofA

BofA raised the firm’s price target on Neurocrine (NBIX) to $184 from $182 and keeps a Buy rating on the shares. The firm, which highlights ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results